Key terms
About NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NTRA news
Apr 17
5:31am ET
TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks
Apr 11
8:08am ET
Natera announces publication of dd-cfDNA study data
Apr 08
9:01am ET
Analysts Offer Insights on Healthcare Companies: Natera (NTRA) and Inotiv (NOTV)
Apr 08
8:49am ET
Natera assumed with a Buy at Craig-Hallum
Apr 08
8:03am ET
Natera announces new data from two studies on Prospera Heart dd-cfDNA test
Apr 05
8:09am ET
Natera upgraded to Outperform from Market Perform at Bernstein
Apr 05
7:01am ET
Natera announces surveillance analysis from IMvigor011 study
Apr 03
1:52am ET
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)
Apr 01
8:16am ET
Natera launches Alliance A032103 utilizing Signatera MRD test for MIUC
Mar 18
7:12am ET
Natera announces CIRCULATE-PRODIGE-70 study in France
Mar 06
7:35am ET
Piper Sandler Sticks to Its Buy Rating for Natera (NTRA)
Mar 06
7:23am ET
Natera price target raised to $110 from $70 at Piper Sandler
Mar 01
1:03am ET
New Share Price & Shareholder Rights Risk for Natera Inc. – What’s the Latest?
Mar 01
12:57am ET
Natera’s Strong Q4 Performance and Positive Outlook Merit Buy Rating and $90 Price Target
Feb 29
12:33pm ET
CMS announcement positive for CareDx and Natera, says Craig-Hallum
Feb 29
12:30pm ET
CMS says transplant patients can continue to access blood tests
Feb 29
7:54am ET
Natera price target raised to $110 from $87 at TD Cowen
Feb 29
7:50am ET
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Jazz Pharmaceuticals (JAZZ) and Natera (NTRA)
Feb 29
7:43am ET
Natera price target raised to $100 from $87 at Canaccord
Feb 29
7:24am ET
Natera price target raised to $100 from $90 at BTIG
Feb 29
6:36am ET
Natera price target raised to $104 from $70 at UBS
Feb 29
12:05am ET
Natera’s Strong Q4 Performance and Market Positioning Warrant a Buy Rating with Increased Price Target
Feb 28
4:38pm ET
Natera sees FY24 revenue $1.32B-$1.35B, consensus $1.27B
Feb 28
4:37pm ET
Natera reports FY23 EPS ($3.78), consensus ($3.86)
Feb 28
5:30am ET
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Natera (NTRA) and Syndax Pharmaceuticals (SNDX)
Feb 27
11:38pm ET
Natera’s Signatera Assay Poised for Growth Amid Medicare Expansion and Potential NCCN Inclusion
Feb 27
8:25am ET
Natera announces next phase of CareDx patent infringement litigation
Feb 26
9:58am ET
Canaccord bullish on Natera growth potential as Medicare extends coverage
Feb 26
9:10am ET
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Natera (NTRA) and Agiliti (AGTI)
Feb 26
7:19am ET
Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
Feb 20
8:02am ET
Natera downgraded to Outperform from Strong Buy at Raymond James
No recent press releases are available for NTRA
NTRA Financials
Key terms
Ad Feedback
NTRA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NTRA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
